Vantage Hemp is delighted to announce our partnership with Medcan Australia, to supply the company with pharmaceutical-grade CBD oils, distillates and isolates.The supply agreement symbolizes Vantage’s expansion into the Australian market, supporting our mission to deliver premium trusted cannabinoid extracts to medical patients worldwide.
Australian cannabis sales approached $100 million in 2020, with 50,000 active patients. As the market gathers pace, aligning with Medcan empowers both companies to meet the demand for exceptional CBD products, strengthen the global supply chain and reinforce their respective leadership positions.
Licensed to import, cultivate, manufacture and export medicinal cannabis, Medcan was founded in 2016 with a commitment to provide Australians with high-quality fairly priced products. Through vertical integration, the company has become a front runner in the regional market, with Vantage Hemp ensuring the superior quality, composition and reliability of its medical portfolio. The Australian market is poised for substantial growth in the near future, reaching $1.9 billion by 2026. The flourishing industry, combined with a buoyant economy, presents lucrative opportunities for cannabis companies.
Importance of strategic partnerships
By aligning with those that share Vantage’s dedication to provide CBD products that benefit from science-driven consistency, sustainability and transparency, the company can build mutually beneficial relationships across the international cannabis industry. As markets emerge and expand, these alliances provide the agility and infrastructure to capitalize on new opportunities and reach untapped audiences.
Cannabis markets are at different levels of maturity, without a universal standard for medicinal products. Rigorous regional certification processes for extraction companies increases the value of partners licensed in a variety of territories. Vantage Hemp is one of the most accredited cannabinoid extractors in the world. It has achieved EU compliance, North American GMP compliance, and the internationally recognized ICH Q7 GMP and WHO GMP certifications, which endorse the company’s CBD extracts as the highest standard found anywhere in the world.
Vantage Hemp has had a global outlook since its inception, recognizing the potential for CBD to transform healthcare internationally. This visionary mindset, combined with a pharmaceutical approach, has elevated the company to achieve global recognition.
Analysts predict the international industry will surpass $28.5 billion by 2027. With attitudes and laws rapidly changing across the world, exciting markets are emerging with significant advantages to be gained from strategic mutually beneficial alliances. As medicinal frameworks mature, the possibilities for well-established GMP compliant cannabinoid manufacturers are endless.
If you are interested in working with Vantage Hemp or learning more about our products contact us at [email protected]